Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
